evidence table

Ginkgo Cognitive Performance Randomized Trial Evidence Table

Name: Ginkgo Cognitive Performance Randomized Trial Evidence Table
Creator: Migaku
License: https://creativecommons.org/licenses/by/4.0/

Structured evidence table for Ginkgo Cognitive Performance Randomized Trial, generated from 2 reusable source documents in the Migaku knowledge base.

topic	claim	evidence level	citation	source
Ginkgo Cognitive Performance Randomized Trial	The second study confirmed the GBP benefits on mood states and a visually consistent downward trend in reaction times across all four cognitive performance tests at both GBP dosages, suggesting improved processing speed in response to various stimuli.	2	Hawkins K (2026)	Health Benefits of a Standardized <i>Ginkgo biloba</i> Extract Associated With Phosphatidylserine in Alleviating Mental Stress and Cognitive Performance: Results From Two Exploratory Randomized Trials.
Ginkgo Cognitive Performance Randomized Trial	Mental health is threatened every day by the stressors of life: frenetic work rhythms, stressful conditions can generate anxiety, depression, cognition, and sleep problems.	2	Hawkins K (2026)	Health Benefits of a Standardized <i>Ginkgo biloba</i> Extract Associated With Phosphatidylserine in Alleviating Mental Stress and Cognitive Performance: Results From Two Exploratory Randomized Trials.
Ginkgo Cognitive Performance Randomized Trial	Among natural products with properties to support mental health, Gingko biloba extract with phosphatidylserine (GBP) was exploited with the aim of evaluating its benefits in cognitive function, mood regulation, and overall quality of life.	2	Hawkins K (2026)	Health Benefits of a Standardized <i>Ginkgo biloba</i> Extract Associated With Phosphatidylserine in Alleviating Mental Stress and Cognitive Performance: Results From Two Exploratory Randomized Trials.
Ginkgo Cognitive Performance Randomized Trial	These limitations have catalyzed an increased global focus on nutraceuticals and phytomedicines possessing multimodal biological activities that transcend mere monoamine reuptake inhibition.	3	Li Xikun (2026)	Rhodiola rosea , Ginkgo biloba , and Ashwagandha as novel antidepressant supplements: converging monoaminergic, neurotrophic, anti-inflammatory, and brain health pathways in depressive disorders
Ginkgo Cognitive Performance Randomized Trial	Unlike prior reviews that focus on individual herbs or broadly defined adaptogens, the present review integrates mechanistic, preclinical, and clinical evidence across these three agents to highlight their complementary rather than redundant actions.	3	Li Xikun (2026)	Rhodiola rosea , Ginkgo biloba , and Ashwagandha as novel antidepressant supplements: converging monoaminergic, neurotrophic, anti-inflammatory, and brain health pathways in depressive disorders
Ginkgo Cognitive Performance Randomized Trial	Rhodiola rosea Ginkgo biloba Withania somnifera A comprehensive and structured literature search was conducted to identify preclinical, translational, and clinical evidence related to the antidepressant effects and underlying neurobiological mechanisms of,, and(Ashwagandha).	3	Li Xikun (2026)	Rhodiola rosea , Ginkgo biloba , and Ashwagandha as novel antidepressant supplements: converging monoaminergic, neurotrophic, anti-inflammatory, and brain health pathways in depressive disorders
Ginkgo Cognitive Performance Randomized Trial	1 2 3 Rhodiola rosea Ginkgo biloba Withania somnifera Depression constitutes one of the most incapacitating neuropsychiatric disorders globally ().	3	Li Xikun (2026)	Rhodiola rosea , Ginkgo biloba , and Ashwagandha as novel antidepressant supplements: converging monoaminergic, neurotrophic, anti-inflammatory, and brain health pathways in depressive disorders